Turn Biotechnologies (turn.bio) is at the forefront of developing innovative anti-aging treatments through advanced mRNA technology. Their focus lies in rejuvenating cells by resetting the epigenome, which governs gene expression and cell function. This approach promises to restore youthful functionality to aging cells, potentially revolutionizing how we treat age-related diseases.
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The Solution
Central to Turn Biotechnologies’ strategy is their proprietary Epigenetic Reprogramming of Age (ERA™) technology. Unlike traditional methods that either clone cells or revert them to a pluripotent state, ERA™ targets age-related cellular decline while preserving cell identity. This involves modifying the epigenetic marks that accumulate over time, thereby enhancing cells’ natural abilities to combat disease and repair damage.
The applications of Turn Biotechnologies’ technology are extensive. Their research and development pipeline includes treatments for chronic conditions like osteoarthritis and macular degeneration. By rejuvenating specific cell types, these therapies aim to improve healthspan and quality of life, addressing the underlying causes of aging rather than just symptoms.
Given the broad span of applications the official pipeline is quite extensive, with a couple of programs currently in the preclinical phase.
You can view their official pipeline in the below image from their website:
As shown by their pipeline all of their programs are still in the early stages of development. It will be interesting to follow the most advanced programs entering clinical trials to see if their technology is indeed capable of scientific breakthroughs.
Turn Biotechnologies is committed to translating these potential scientific breakthroughs into tangible therapies. As they progress with ERA™ technology, the potential to significantly impact age-related diseases and enhance human healthspan will hopefully become increasingly attainable.
The Company
Turn Biotechnologies was founded in 2019 by Sergio Ruiz, Jay Sarkar, Marco Quarta, and Vittorio Sebastiano. The company is headquartered in Mountain View, California, and Anja Krammer serves as the CEO.
Turn Biotechnologies has successfully raised substantial funding to support its innovative research. The company has raised $29 million over several rounds of funding. The latest funding round took place in April of 2022. Key investors include Khosla Ventures, Shanda Group, Formic Ventures, Methuselah Fund, and Methuselah Foundation.
The company is exploring partnerships to further its research and development efforts. They are in discussions with various potential partners, aiming to leverage their technology for a broader impact on age-related conditions
Read about more anti-aging companies on this website through this link.
